Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Nov;31(11):2529-2531.
doi: 10.1038/leu.2017.247. Epub 2017 Aug 3.

Sustained Deep Molecular Responses in Patients Switched to Nilotinib Due to Persistent BCR-ABL1 on Imatinib: Final ENESTcmr Randomized Trial Results

Affiliations
Free PMC article
Clinical Trial

Sustained Deep Molecular Responses in Patients Switched to Nilotinib Due to Persistent BCR-ABL1 on Imatinib: Final ENESTcmr Randomized Trial Results

T P Hughes et al. Leukemia. .
Free PMC article

Conflict of interest statement

The authors declare the following relationships: TPH: Novartis (research funding, honoraria, board of directors or advisory board membership), Bristol-Myers Squibb (research funding, honoraria, board of directors or advisory board membership), Ariad (research funding, honoraria, board of directors or advisory board membership); BL: Novartis (consultancy, honoraria, speakers bureau, board of directors or advisory board membership); FC: Novartis (honoraria, speakers bureau), Ariad (speakers bureau), Bristol-Myers Squibb (speakers bureau); APS: Novartis (honoraria), Bristol-Myers Squibb (honoraria), Pfizer (honoraria), Celgene (honoraria); F-XM: Bristol-Myers Squibb (consultancy, honoraria), Novartis (consultancy, research funding, honoraria), Pfizer (honoraria), Ariad (honoraria); DR: Novartis (honoraria), Ariad (honoraria), Bristol-Myers Squibb (honoraria), Pfizer (honoraria); AG-B: Novartis (honoraria), Amgen (honoraria), Bristol-Myers Squibb (consultancy, honoraria), Pfizer (honoraria); SA: Novartis (employment); TG: Novartis (employment); DD: Novartis (employment); SB: Novartis (research funding, honoraria, speakers bureau, board of directors or advisory board membership), Qiagen (honoraria, board of directors or advisory board membership), Ariad (research funding); JHL: Novartis (consultancy, research funding, honoraria, board of directors or advisory board membership), Ariad (consultancy, research funding, honoraria, board of directors or advisory board membership), Bristol-Myers Squibb (consultancy, research funding, honoraria, board of directors or advisory board membership), Pfizer (consultancy, research funding, honoraria, board of directors or advisory board membership). The remaining authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Time to Achievement of First MR4.5 (ITT population). ITT, intention-to-treat; MR4.5, BCR-ABL1 ⩽0.0032% on the International Scale.

Similar articles

See all similar articles

Cited by 8 articles

See all "Cited by" articles

References

    1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872–884. - PMC - PubMed
    1. National Comprehensive Cancer Network2017; NCCN clinical practice guidelines in oncology: chronic myeloid leukemia. 2017; v2.2017.
    1. Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553–561. - PubMed
    1. Kantarjian HM, Talpaz M, O'Brien S, Jones D, Giles F, Garcia-Manero G et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108: 1835–1840. - PubMed
    1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417. - PubMed

Publication types

MeSH terms

Substances

Feedback